Crohn's disease treatment from Janssen wins FDA approval
Janssen's Stelara or ustekinumab has been approved by the FDA as a treatment for moderately to severely active Crohn's dise More
View ArticleFDA approves Janssen Biotech's STELARA for Crohns disease
The US Food and Drug Administration FDA has approved Janssen Biotech's STELARA ustekinumab to treat moderately to severely active Crohns disease in adults 18 years or older who have failed or were...
View ArticleStelara gains US approval for CrohnÂs disease
JanssenÂs Stelara has gained FDA approval for use in patients with CrohnÂs disease who have failed treatment or were intolerant to a TNF blocker drug.The monoclonal antibody drug targets interleukin...
View ArticleJ&Js Stelara wins US nod for Crohns
US regulators have expanded the reach of Johnson & Johnson group Janssen Biologics' psoriasis blockbuster Stelara to include the treatment of patients with Crohn's disease.
View ArticleCrohn's & Colitis Foundation of America Pilot Program Reveals Best Practices...
NEW YORK Sept.&160;27 2016 PRNewswireUSNewswire &160;IBD Qorus&8482; the Crohn's & Colitis Foundation of America's CCFA national initiative to improve the quality of care for...
View ArticleGalapagos NV Successful completion of regulatory consultations to progress...
Global program to start in Q4'16 DIVERSITY Phase 3 study in Crohn's disease SELECTION Phase 2b3 study in ulcerative colitis 100 mg and 200 mg once daily doses included Mechelen Belgium; 27 Septe...
View ArticleSuccessful completion of regulatory consultations to progress filgotinib to...
  Global program to start in Q4'16 DIVERSITY Phase 3 study in Crohn's disease SELECTION Phase 2b3 study in ulcerative colitis 100 mg and 200 mg once daily doses included
View ArticleBRIEFZeria Pharmaceutical gets manufacture and marketing approval for...
Says it gets manufacture and marketing approval forZentacort Capsules 3mg Budesonide as treatment for Crohn'sdisease
View ArticleAdditional Interim Data Supporting LongTerm Use of Vedolizumab in Patients...
OSAKA Japan Sept. 28 2016 PRNewswire &160;Takeda Pharmaceutical Company Limited TSE 4502 "Takeda" announced that two interim reports from the ongoing openlabel GEMINI longterm safety LTS study...
View ArticleTV Star Shemar Moore and Mediaplanet Shed Light on Autoimmune Diseases
Mediaplanet today announces the launch of this falls edition of Autoimmune Diseases.New York NY PRWEB September 28 2016 This campaign will advocate for those living with autoimmune diseases like...
View ArticleUpdated & Expanded Commentary Prepping for Prothena's Immiment Announcements...
For the past few weeks we have maintained that Prothena was going to update its plans regarding PRX003 in September 2016. Prothena announced that it will host a conference call on Thursday September 29...
View ArticleNew How To Invisible Illness Workbooks by Jessie Riley Help Chronically Ill...
Jessie Riley author of The Invisible Cosmic Zebra Collection of 18 creative howto workbooks for 18 invisible illnesses is making a difference in the lives of people she has never met. She penned the...
View ArticleRegen BioPharma Inc. Announces the Appointment of Xiaojing Ma PhD as the...
SAN DIEGO September 29 2016 PRNewswire Regen BioPharma Inc. OTCQB RGBP OTCQB RGBPP is pleased to announce that Xiaojing Ma Ph.D. has agreed to serve in the consulting role as the Company's Senior...
View ArticleJohnson & Johnsons Stelara receives FDA approval
The drug is approved for use to treat the skin condition scaly plaque psoriasis and a type of arthritis associated with psoriasis. Crohn's disease is a chronic inflammatory condition in the...
View ArticleFungus May Be 'Key Factor' in Crohn's Disease
A fungus in the gut could be a key factor in the development of Crohn's disease according to an investigation by an international team of researchers. WebMD Health News
View ArticleAdditional interim data supporting longterm use of vedolizumab in...
Takeda Pharmaceutical Company Limited announced that two interim reports from the ongoing openlabel GEMINI longterm safety study describing clinical data of longterm Entyvio treatment in patients with...
View ArticlePrime Therapeutics Finds Autoimmune Specialty Drug Spend has Doubled Accounts...
ST. PAUL Minn. Sept. 30 2016 PRNewswire In the past four years spending on autoimmune drugs has doubled and utilization has jumped nearly 40 percent in a population of 4.4 million commerciallyinsured...
View ArticleImproveCareNow Network Wins $100000 Drucker Prize
The Drucker Institute announced that the ImproveCareNow Network is the winner of the 2016 Drucker Prize.Claremont Calif. PRWEB September 30 2016 Today the Drucker Institute at Claremont Graduate...
View ArticleAllergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain...
DUBLIN Oct. 3 2016 PRNewswire &160;Allergan plc NYSE AGN today announced that it has entered into a licensing agreement with MedImmune AstraZeneca's global biologics research and development arm...
View Article